Joshy Jacob

Dr. Joshy Jacob


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2016 in Nature Communications
Verified
Journal Article
Open access
CBCaitlin Bohannon
Caitlin Bohannon
RPRyan Powers
Ryan Powers
LSLakshmipriyadarshini Satyabhama
Lakshmipriyadarshini Satyabhama
ACAng Cui
Ang Cui
CTChristopher Tipton
Christopher Tipton
JJJoshy Jacob
Joshy Jacob
Long-lived plasma cells are critical to humoral immunity as a lifelong source of protective antibodies. Antigen-activated B cells—with T-cell help—undergo affinity maturation within germinal centres and persist as long-lived IgG plasma cells in the bone marrow. Here we show that antigen-specific, induced IgM plasma cells also persist for a lifetime. Unlike long-lived IgG plasma cells, which develop in germinal centres and then home to the bone marrow, IgM plasma cells are primarily retained within the spleen and can develop even in the absence of germinal centres. Interestingly, their expressed IgV loci exhibit somatic mutations introduced by the activation-induced cytidine deaminase (AID). However, these IgM plasma cells are probably not antigen-selected, as replacement mutations are spread through the variable segment and not enriched within the CDRs. Finally, antibodies from long-lived IgM plasma cells provide protective host immunity against a lethal virus challenge.

1 January 2007 in BMC Immunology
Verified
Journal Article
Open access
PDF file
CMCharles H Maris
Charles H Maris
CCCraig P Chappell
Craig P Chappell
JJJoshy Jacob
Joshy Jacob
Infection of mice with the Armstrong strain of lymphocytic choriomeningitis virus (LCMVARM) leads to a robust immune response and efficient viral clearance. This is in contrast to infection with the variant strain LCMVClone13, which causes functional inactivation of effector T cells and viral persistence. The mechanism by which LCMVClone13 suppresses the antiviral immune response and persists in its host is unknown.

1 April 2019 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
JSJessica R. Shartouny
Jessica R. Shartouny
JJJoshy Jacob
Joshy Jacob

12 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SLSong Hee Lee
Song Hee Lee
EKEui Ho Kim
Eui Ho Kim
JOJustin T. O’neal
Justin T. O’neal
GDGordon Dale
Gordon Dale
DHDavid J. Holthausen
David J. Holthausen
JJJoshy Jacob
Joshy Jacob
Zika virus (ZIKV) has emerged as a serious health threat in the Americas and the Caribbean. ZIKV is transmitted by the bite of an infected mosquito, sexual contact, and blood transfusion. ZIKV can also be transmitted to the developing fetus in utero, in some cases resulting in spontaneous abortion, fetal brain abnormalities, and microcephaly. In adults, ZIKV infection has been correlated with Guillain–Barre syndrome. Despite the public health threat posed by ZIKV, neither a vaccine nor antiviral drugs for use in humans are currently available. We have identified an amphibian host defense peptide, Yodha, which has potent virucidal activity against ZIKV. It acts directly on the virus and destroys Zika virus particles within 5 min of exposure. The Yodha peptide was effective against the Asian, African, and South American Zika virus strains and has the potential to be developed as an antiviral therapeutic in the fight against Zika virus. The peptide was also effective against all four dengue virus serotypes. Thus, Yodha peptide could potentially be developed as a pan-therapeutic for Zika and dengue viruses.


1 January 2004 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
HHHuiming Hon
Huiming Hon
JJJoshy Jacob
Joshy Jacob